The EMA report also contains information on the third nitrosamine contamination by NMBA. In the beginning of July 2019,
In February 2019, the Committee for Medicinal Products for Human Use (CHMP) of the EMA published a first conclusion on the case of valsartan and other
Glossary of nitrosamines:
EMA: Report on new limits
> Do not hesitate, we look forward to your feedback!
Write a comment on this news.